nach oben

Erschienen in:

08.12.2016 | Original Paper

Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock

verfasst von: Christian Jung, Georg Fuernau, Ingo Eitel, Steffen Desch, Gerhard Schuler, Malte Kelm, Volker Adams, Holger Thiele

Erschienen in: Clinical Research in Cardiology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite the improvement of therapeutic options for patients in acute myocardial infarction (AMI), cardiogenic shock (CS) remains a complication with high mortality rates. Organ failure centrally determines the prognosis of these high-risk patients. Aim of the current study was to assess the incidence of hypoxic hepatitis (HH) in CS, its laboratory detection evaluating novel and established biomarkers and to estimate the prognostic relevance of HH in current clinical practice.

Methods

In 172 patients with CS complicating AMI, blood samples were collected at admission and after 1 day as prespecified subanalysis of the intra-aortic balloon pumping IABP-SHOCK II trial. Classic parameters of HH were measured in addition to argininosuccinate synthase 1 and sulfotransferase isoform SULT2A1 was determined as new biomarker using standard enzyme-linked immunosorbent assay kits. All-cause mortality at 30 days was used for outcome assessment.

Results

The overall mortality rate was 40%. The incidence of HH with an increase of aminotransferase levels to be 20 times above the upper normal level was 18%. Patients with HH had a distinctly higher 30-day mortality rate compared to patients without HH (68 vs. 34%; p < 0.001). After multivariable adjustment aspartate-aminotransferase (ASAT) remained an independent predictor of 30-day mortality together with serum lactate and serum creatinine, while the new biomarkers failed to predict outcome. Comparing different liver markers using receiver operating characteristic analysis, ASAT showed the highest area under the curve for the prediction of outcome.

Conclusions

HH occurs frequently in CS and is associated with particular poor outcome. As conventional biomarker, ASAT is the strongest laboratory predictor of outcome.

ClinicalTrials.gov Identifier: NCT00491036.

Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J (2009) Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119(9):1211–1219. doi:10.1161/CIRCULATIONAHA.108.814947 CrossRefPubMedPubMedCentral

Fengler K, Fuernau G, Desch S, Eitel I, Neumann FJ, Olbrich HG, de Waha A, de Waha S, Richardt G, Hennersdorf M, Empen K, Hambrecht R, Fuhrmann J, Bohm M, Poess J, Strasser R, Schneider S, Schuler G, Werdan K, Zeymer U, Thiele H (2015) Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol 104(1):71–78. doi:10.1007/s00392-014-0767-2 CrossRefPubMed

Jung C, Ferrari M, Roediger C, Fritzenwanger M, Goebel B, Lauten A, Pfeifer R, Figulla HR (2009) Evaluation of the sublingual microcirculation in cardiogenic shock. Clin Hemorheol Microcirc 42(2):141–148PubMed

Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, Fraisse F, Dinh-Xuan AT, Carli P, Spaulding C, Dhainaut JF, Cavaillon JM (2002) Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106(5):562–568CrossRefPubMed

Richardt G, Munch G, Neumann FJ, Rauch B, Kurz T (1997) Systemic and cardiac catecholamines during elective PTCA and during immediate PTCA for acute myocardial infarction. Basic Res Cardiol 92(1):52–60CrossRefPubMed

Thiele H, Ohman EM, Desch S, Eitel I, de Waha S (2015) Management of cardiogenic shock. Eur Heart J 36(20):1223–1230. doi:10.1093/eurheartj/ehv051 CrossRefPubMed

Kramer L, Jordan B, Druml Wv, Bauer P, Metnitz PG, Austrian Epidemiologic Study on Intensive Care ASG (2007) Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study. Crit Care Med 35(4):1099–1104. doi:10.1097/01.CCM.0000259462.97164.A0 CrossRefPubMed

Jung C, Kelm M, Westenfeld R (2016) Liver function during mechanical circulatory support: from witness to prognostic determinant. Crit Care 20(1):134. doi:10.1186/s13054-016-1312-7 CrossRefPubMedPubMedCentral

Chavez-Tapia NC, Balderas-Garces BV, Meza-Meneses P, Herrera-Gomar M, Garcia-Lopez S, Gonzalez-Chon O, Uribe M (2014) Hypoxic hepatitis in cardiac intensive care unit: a study of cardiovascular risk factors, clinical course, and outcomes. Ther Clin Risk Manag 10:139–145. doi:10.2147/TCRM.S59312 CrossRefPubMedPubMedCentral

10.

Fuhrmann V, Jager B, Zubkova A, Drolz A (2010) Hypoxic hepatitis - epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 122(5–6):129–139. doi:10.1007/s00508-010-1357-6 CrossRefPubMed

11.

Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P (2011) Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 37(8):1302–1310. doi:10.1007/s00134-011-2248-7 CrossRefPubMed

12.

Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, Blei AT, Fontana RJ, McGuire BM, Rossaro L, Smith AD, Acute Liver Failure Study G, Lee WM (2007) Intensive care of patients with acute liver failure: recommendations of the US Acute Liver Failure Study Group. Crit Care Med 35(11):2498–2508. doi:10.1097/01.CCM.0000287592.94554.5F CrossRefPubMed

13.

Svetlov SI, Xiang Y, Oli MW, Foley DP, Huang G, Hayes RL, Ottens AK, Wang KK (2006) Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches. Biomarkers 11(4):355–369. doi:10.1080/13547500600775110 CrossRefPubMed

14.

Prima V, Cao M, Svetlov SI (2013) ASS and SULT2A1 are novel and sensitive biomarkers of acute hepatic injury-A comparative study in animal models. J Liver 2(1)

15.

Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Bohm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Mollmann H, Schneider S, Ebelt H, Werdan K, Zeymer U (2012) Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 163(6):938–945. doi:10.1016/j.ahj.2012.03.012 CrossRefPubMed

16.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G, Intraaortic Balloon Pump in cardiogenic shock IIti (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382(9905):1638–1645. doi:10.1016/S0140-6736(13)61783-3 CrossRefPubMed

17.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, Investigators I-SIT (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287–1296. doi:10.1056/NEJMoa1208410 CrossRefPubMed

18.

Fuernau G, Fengler K, Desch S, Eitel I, Neumann FJ, Olbrich HG, de Waha A, de Waha S, Richardt G, Hennersdorf M, Empen K, Hambrecht R, Jung C, Bohm M, Poss J, Strasser RH, Schneider S, Ouarrak T, Schuler G, Werdan K, Zeymer U, Thiele H (2016) Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol. doi:10.1007/s00392-016-1017-6

19.

Fuernau G, Poenisch C, Eitel I, de Waha S, Desch S, Schuler G, Adams V, Werdan K, Zeymer U, Thiele H (2014) Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial. Eur J Heart Fail 16(8):880–887. doi:10.1002/ejhf.117 CrossRefPubMed

20.

Jung C, Fuernau G, de Waha S, Eitel I, Desch S, Schuler G, Figulla HR, Thiele H (2015) Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy. Clin Res Cardiol 104(8):679–687. doi:10.1007/s00392-015-0833-4 CrossRefPubMed

21.

Jung C, Kelm M (2015) Evaluation of the microcirculation in critically ill patients. Clin Hemorheol Microcirc 61(2):213–224. doi:10.3233/CH-151994 CrossRefPubMed

22.

Buerke M, Russ M, Prondzinsky R, Werdan K (2009) Infarct-related cardiogenic shock—diagnosis, monitoring and therapy. Intensivmed 46:132–146CrossRef

23.

Jung C, Janssen K, Kaluza M, Fuernau G, Poerner TC, Fritzenwanger M, Pfeifer R, Thiele H, Figulla HR (2016) Outcome predictors in cardiopulmonary resuscitation facilitated by extracorporeal membrane oxygenation. Clin Res Cardiol 105(3):196–205. doi:10.1007/s00392-015-0906-4 CrossRefPubMed

24.

Jung C, Schlosser M, Figulla HR, Ferrari M (2008) Providing macro- and microcirculatory support with the lifebridge system during high-risk PCI in cardiogenic shock. Heart Lung Circ 18(4):296–298CrossRefPubMed

25.

Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46(14):1063–1070CrossRefPubMed

26.

Raurich JM, Llompart-Pou JA, Ferreruela M, Colomar A, Molina M, Royo C, Ayestaran I, Ibanez J (2011) Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 25(1):50–56. doi:10.1007/s00540-010-1058-3 CrossRefPubMed

27.

Drolz A, Saxa R, Scherzer T, Fuhrmann V (2011) Extracorporeal artificial liver support in hypoxic liver injury. Liver Int 31(Suppl 3):19–23. doi:10.1111/j.1478-3231.2011.02583.x CrossRefPubMed

28.

van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA (2010) Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 16(1):84–90. doi:10.1016/j.cardfail.2009.08.002 CrossRefPubMed

29.

Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF (2013) Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 61(24):2397–2405. doi:10.1016/j.jacc.2013.03.042 CrossRefPubMed

30.

Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WH, Mullens W (2013) Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 62(6):485–495. doi:10.1016/j.jacc.2013.04.070 CrossRefPubMed

31.

Denis C, De Kerguennec C, Bernuau J, Beauvais F, Cohen Solal A (2004) Acute hypoxic hepatitis (‘liver shock’): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 6(5):561–565. doi:10.1016/j.ejheart.2003.12.008 CrossRefPubMed

32.

Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR, Investigators R-A (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61(2):196–206. doi:10.1016/j.jacc.2012.11.005 CrossRefPubMed

33.

Drolz A, Horvatits T, Michl B, Roedl K, Schellongowski P, Holzinger U, Zauner C, Heinz G, Madl C, Trauner M, Fuhrmann V (2014) Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. J Hepatol 60(6):1187–1193. doi:10.1016/j.jhep.2014.01.019 CrossRefPubMed

34.

Porres-Aguilar M, Gallegos-Orozco JF (2014) Hepatopulmonary syndrome: Is it time to redefine the MELD exception score for better organ allocation and outcomes? Ann Hepatol 13(4):468–470PubMed

35.

Warkentin TE, Pai M (2016) Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’ the unrecognized provocateur of ischemic limb necrosis? J Thromb Haemost 14(2):231–235. doi:10.1111/jth.13219 CrossRefPubMed

36.

Teng R (2015) Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet 54(11):1125–1138. doi:10.1007/s40262-015-0290-2 CrossRefPubMedPubMedCentral

37.

Kortgen A, Paxian M, Werth M, Recknagel P, Rauchfuss F, Lupp A, Krenn CG, Muller D, Claus RA, Reinhart K, Settmacher U, Bauer M (2009) Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock 32(4):358–365. doi:10.1097/SHK.0b013e31819d8204 CrossRefPubMed

Titel: Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock
verfasst von: Christian Jung
Georg Fuernau
Ingo Eitel
Steffen Desch
Gerhard Schuler
Malte Kelm
Volker Adams
Holger Thiele
Publikationsdatum: 08.12.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 5/2017
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-016-1060-3

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems

Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis

Erratum to: Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry

Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome

Coronary steal syndrome after left internal mammary bypass in a patient with undiagnosed Takayasu arteritis

Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie